Related Experiment Video
Updated: Jan 13, 2026
Characterization of Immune Cell-derived Extracellular Vesicles and Studying Functional Impact on Cell Environment
Published on: June 2, 2020
Small Extracellular Vesicles Derived from NF2-Associated Schwannoma Cells Modulate Tumor Progression and Immunity via
Ying Wang1, Yuan Ren2, Qi Zhang3
1Department of Neural Reconstruction, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
Abstract:
In-depth exploration of tumor immune suppression mechanisms may provide new therapeutic options for NF2-associated tumors. In this study, we found that sEVs secreted by NF2-associated schwannomas (NF2-EVs) facilitate the conversion of CD14+ monocytes into an MDSC-like phenotype, showcasing MDSC-like inhibitory functions. Moreover, these NF2-EVs are capable of enhancing tumor cell proliferation. Through proteomic analysis and subsequent validation of the NF2-EVs, we identified elevated levels of HSP90. When we knocked down HSP90 expression in tumor cells, the sEVs secreted showed diminished capacity to convert monocytes into MDSCs and a reduced ability to promote tumor cell proliferation. Conversely, sEVs secreted by tumor cells that overexpress HSP90 displayed the opposite effects. Further mechanistic studies revealed that HSP90 could influence the expression of AKT/p-AKT and ERK/p-ERK. Our results suggest that NF2 tumor cells could regulate the AKT/p-AKT and ERK/p-ERK pathways to promote tumor cell proliferation and the formation of an immunosuppressive microenvironment by secreting sEVs' HSP90, offering valuable insights into the involvement of HSP90 in exosome-mediated communication within the context of NF2-related schwannomatosis (NF2-SWN). This information has the potential to inform the design of effective immunotherapeutic protocols and offer new treatment options for NF2-SWN patients.
Insights
NF2 tumor cells release exosomes containing HSP90, which promote tumor growth and immune suppression by converting monocytes into myeloid-derived suppressor cells (MDSCs). Targeting HSP90 may offer new NF2-SWN treatments.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Neurofibromatosis type 2 (NF2)-associated schwannomas are tumors with limited therapeutic options.
- Understanding tumor immune suppression mechanisms is crucial for developing novel treatments.
Purpose of the Study:
- To investigate the role of small extracellular vesicles (sEVs) secreted by NF2-associated schwannoma cells in modulating the tumor microenvironment.
- To identify key molecules within these sEVs responsible for immune suppression and tumor promotion.
Main Methods:
- Proteomic analysis of sEVs from NF2-associated schwannoma cells (NF2-EVs).
- Functional assays assessing the effect of NF2-EVs on monocyte differentiation into myeloid-derived suppressor cells (MDSCs).
- Evaluation of NF2-EVs' impact on tumor cell proliferation.
- Mechanistic studies involving HSP90 knockdown and overexpression, and analysis of AKT/ERK signaling pathways.
Main Results:
- NF2-EVs promote the conversion of CD14+ monocytes into MDSC-like cells with immunosuppressive functions.
- NF2-EVs enhance tumor cell proliferation.
- Elevated levels of Heat Shock Protein 90 (HSP90) were identified in NF2-EVs.
- HSP90 knockdown in tumor cells reduced the immunosuppressive and tumor-promoting capacity of secreted sEVs.
- HSP90 influences the expression of AKT/p-AKT and ERK/p-ERK signaling pathways.
Conclusions:
- NF2 tumor cells utilize HSP90-containing sEVs to foster an immunosuppressive microenvironment and enhance tumor growth.
- HSP90 mediates these effects by influencing AKT and ERK signaling pathways.
- Targeting HSP90 and exosome-mediated communication presents a potential therapeutic strategy for NF2-related schwannomatosis (NF2-SWN).
